Policy & Regulation
Ipsen completes Memo Therapeutics acquisition to strengthen rare disease pipeline
22 July 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Wednesday that it has completed the acquisition of Memo Therapeutics AG, adding late-stage asset pot...
Hugel Aesthetics expands US presence
22 July 2026 - Australian pharmaceutical company Hugel Aesthetics announced on Tuesday a major expansion of its US business as part of its long-term growth strategy.The expansion includes the launch o...
WuXi AppTec named to FTSE4Good Index Series for fourth consecutive year
22 July 2026 - WuXi AppTec, a China-based global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organisation), announced on Tuesday that it has been named in the FTSE4Good Ind...
European Commission expands Crysvita approval to infants with XLH
21 July 2026 - Kyowa Kirin EMEA, a subsidiary of Japanese pharmaceutical company Kyowa Kirin Co Ltd (TSE:4151), said on Tuesday that the European Commission has approved an expanded indication for Cry...
Akagera Medicines reports positive first-in-human data for AKG-100
21 July 2026 - Clinical-stage biopharmaceutical company Akagera Medicines Inc, together with the TASK Clinical Research Center in South Africa, on Monday announced positive results from the single-asc...
Argo Biopharma doses first participant in Phase I trial of factor XI targeting siRNA therapy
21 July 2026 - Argo Biopharmaceutical Co Ltd, a clinical-stage small interfering RNA (siRNA) therapeutics company, announced on Monday that the first participant has been dosed in its Phase I study of...